Literature DB >> 26040605

The use of radiation therapy in localized high-grade soft tissue sarcoma and potential impact on survival.

Chun-Han Hou1, Alexander L Lazarides, Paul J Speicher, Daniel P Nussbaum, Daniel G Blazer, David G Kirsch, Brian E Brigman, William C Eward.   

Abstract

BACKGROUND: It is a consensus that radiation therapy (RT) should be applied for all large, deep, high-grade soft tissue sarcomas (STS). Therefore, we investigated the National Cancer Database (NCDB) to study how these guidelines are being followed, to determine what factors may be associated with the decision not to use RT, and to see whether there was an association of RT use and survival.
METHODS: We retrospectively analyzed localized high-grade STS patients in the NCDB from 1998 through 2006. They were further stratified into two groups: no radiation (NRT) group and radiation (RT) group. Then, long-term survival between the two groups was evaluated using the Kaplan-Meier (KM) method with comparisons based on the log-rank test. Multiple variables were analyzed between the two groups. Propensity matching was performed secondarily to minimize the influence of confounding variables.
RESULTS: A total of 3982 of 10,290 patients (37.8 %) did not receive RT and 6,308 patients (62.2 %) did receive RT. Patients in the NRT group were more likely to have a below-median education level (median 58.2 % vs. 60.7 %; p = 0.015) and a below-median income level (65.1 % vs. 68.6 %; p < 0.001). In addition, these patients lived farther from their treatment centers (20.2 vs. 14.8 miles, p = 0.002) and were more likely to be uninsured (5.3 % vs. 3.5 %, p < 0.001). They were less likely to receive a radical excision (55.2 % vs. 70.1 %; p < 0.001) and more likely to receive amputation (20.9 % vs. 3.3 %; p < 0.001). The 30-day mortality (1.2 % vs. 0.2 %; p < 0.001) and readmission rate (3.8 % vs. 2.8 %; p = 0.031) were higher for the NRT group. KM analysis showed that long-term survival for patients who did not receive RT was significantly lower, even after propensity score matching (p < 0.001).
CONCLUSIONS: This large database review reveals a striking lack of utilization of RT to treat high-grade STS, which correlates with poorer survival even after propensity matching. Lower education and income levels and diminished access to medical care (insurance and distance to the facility) are associated with failing to receive RT.

Entities:  

Mesh:

Year:  2015        PMID: 26040605     DOI: 10.1245/s10434-015-4639-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Editorial: Beware of Studies Claiming that Social Factors are "Independently Associated" with Biological Complications of Surgery.

Authors:  Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2019-09       Impact factor: 4.176

2.  Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Osteosarcoma: A National Cancer Database Study.

Authors:  Daniel R Evans; Alexander L Lazarides; Mark M Cullen; Julia D Visgauss; Jason A Somarelli; Dan G Blazer; Brian E Brigman; William C Eward
Journal:  Ann Surg Oncol       Date:  2021-05-20       Impact factor: 5.344

3.  Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis.

Authors:  Alicia A Gingrich; Sarah B Bateni; Arta M Monjazeb; Morgan A Darrow; Steven W Thorpe; Amanda R Kirane; Richard J Bold; Robert J Canter
Journal:  Ann Surg Oncol       Date:  2017-07-24       Impact factor: 5.344

4.  Adherence to National Comprehensive Cancer Network Guidelines is Associated with Improved Survival for Patients with Stage 2A and Stages 2B and 3 Extremity and Superficial Trunk Soft Tissue Sarcoma.

Authors:  Rachel K Voss; Yi-Ju Chiang; Keila E Torres; B Ashleigh Guadagnolo; Gary N Mann; Barry W Feig; Janice N Cormier; Christina L Roland
Journal:  Ann Surg Oncol       Date:  2017-07-24       Impact factor: 5.344

5.  Soft Tissue Sarcoma of the Extremities: What Is the Value of Treating at High-volume Centers?

Authors:  Alexander L Lazarides; David L Kerr; Daniel P Nussbaum; R Timothy Kreulen; Jason A Somarelli; Dan G Blazer; Brian E Brigman; William C Eward
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

6.  Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma: A National Cancer Database Study.

Authors:  Daniel R Evans; Alexander L Lazarides; Mark M Cullen; Jason A Somarelli; Dan G Blazer; Julia D Visguass; Brian E Brigman; William C Eward
Journal:  Ann Surg Oncol       Date:  2021-09-27       Impact factor: 5.344

7.  The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long-term community-based cancer center experience.

Authors:  Jeffrey S Kneisl; Chad Ferguson; Myra Robinson; Anthony Crimaldi; Will Ahrens; James Symanowski; Michael Bates; Jennifer L Ersek; Michael Livingston; Joshua Patt; Edward S Kim
Journal:  Cancer Med       Date:  2017-02-11       Impact factor: 4.452

8.  Improving Long-Term Outcomes for Patients with Extra-Abdominal Soft Tissue Sarcoma Regionalization to High-Volume Centers, Improved Compliance with Guidelines or Both?

Authors:  Sanjay P Bagaria; Yu-Hui Chang; Richard J Gray; Jonathan B Ashman; Steven Attia; Nabil Wasif
Journal:  Sarcoma       Date:  2018-04-03

9.  The Role of Radiotherapy in Soft Tissue Sarcoma on Extremities With Lymph Nodes Metastasis: An IPTW Propensity Score Analysis of the SEER Database.

Authors:  Xinzhu Qiu; Hongbo He; Hao Zeng; Xiaopeng Tong; Qing Liu
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

10.  Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER.

Authors:  Stephen J Ramey; Raphael Yechieli; Wei Zhao; Joyson Kodiyan; David Asher; Felix M Chinea; Vivek Patel; Isildinha M Reis; Lily Wang; Breelyn A Wilky; Ty Subhawong; Jonathan C Trent
Journal:  Cancer Med       Date:  2018-07-20       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.